Mr Charles Walker
Non-Executive Director
pharmaceutical
Imugene
Australia
Biography
Having spent around 20 years in the industry, Imugene NED Charles Walker is best known for his most recent role as CEO of Imugene Ltd, and also CEO, and earlier CFO, of Alchemia Limited. His three year tenure at Alchemia saw the launch and growth of sales of Alchemia’s first marketed product fondaparinux, the initiation of Phase III and Phase II clinical trials of Alchemia’s anti-cancer drug candidate HA-Irinotecan, the establishment of a partnership with Astra Zeneca AB and the establishment of a collaboration with Merck-Serono SA.
Research Interest
pharmaceuticals
